Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

The UK drugmaker AstraZeneca has agreed to acquire Belgian cell therapy developer EsoBiotec for up to $1bn to enhance its cancer treatment capabilities. Read more.

AstraZeneca to acquire EsoBiotec to advance cell therapy ambition Acquisition includes world-leading in vivo delivery platform with potential to transform cell therapy AstraZeneca has ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

Oxford Biomedica plc (OTCMKTS:OXBDF – Get Free Report) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 78,300 shares, an increase of 131.0% ...

OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, has been honoured with a spot on the Financial Times’ prestigious ‘UK Best Employers 2025’ list. This recognition ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...